RxDoctor Payments Data

Nasir Rahmatullah, MD

Cardiology · Kissimmee, FLNPI 1679503684

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,337 of the $1,634 with a category attached, or 81.8%. 19 manufacturers reported payments, led by Astellas Pharma US Inc at 25.5% of the total. Reporting peaked in 2021 at $442 and has fallen 72.0% since, to $124 in 2025.

$1,634in general payments, 2019–2025

Across 71 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$416
  • Boehringer Ingelheim$393
  • Kestra Medical Technology Services, Inc.$153
  • AstraZeneca$141
  • Amgen$115
  • Lilly USA, LLC$56
  • plus $362 from 13 others
$332,941in research payments, 2019–2025

Across 5 payments — averaging $66,588 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$333K

What the payments were for

  • Food & beverage$1,33782%
  • Education$29718%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,634 in reported general payments places this provider in the 60th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$156,731
Medicare patients
227
Services billed
1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$25,165
Isosorbide Mononitrate ErIsosorbide Mononitrate63$1,059
Amiodarone Hcl22$821
Metoprolol Succinate35$722
Carvedilol60$623
Nitroglycerin21$541
Diltiazem Hcl16$362
Losartan Potassium25$256
Atorvastatin Calcium38$239
Enalapril Maleate26$234
ClopidogrelClopidogrel Bisulfate24$140
Amlodipine Besylate21$92
Lisinopril24$86
Furosemide21$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$25,16522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 45 cardiology providers in Florida.

Other cardiology in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →